fbpx

molecules of the month

GSK620

BD2 domain selective BET inhibitor

oral efficacy in 3 inflammation models

from SBDD of a BD2-selective HTS hit

Science, Mar. 19, 2020

GlaxoSmithKline, Stevenage, UK

Structure of pan-BD2 inhibitor GSK620
1 min read

GSK620 (GlaxoSmithKline (GSK) oral in vivo BD2 domain selective BET inhibitor)


request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.


already a member? log in: